• 1

    Breast cancers are molecularly diverse at multiple levels

  • 2

    Several Key challenges to translate genomic data


The challenges in ER+ve breast cancer care?

  • Development of stratified therapeutics for patients to account for inter-tumoural heterogeneity, building on past successes to accelerate the delivery of the right drug to the right patient at the right time based on targeting key molecular drivers.
  • Build frameworks to devise combination therapies to account for intra-tumoural heterogeneity, seeking to target multiple tumour vulnerabilities sequentially or at the same time, being cognizant of the potential for combinatorial toxicities as well as benefit.

This event is sponsored by: :

Comments (0)